

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10692355
	Filing Date		2003-10-23
	First Named Inventor	Robert Davies	
	Art Unit	1624	
	Examiner Name	Kahsay Hable	
	Attorney Docket Number	VPI/00-129-1 DIV US	

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	6653301	B2	2003-11-25	Vertex Pharmaceuticals Incorporated	
	2	6989385	B2	2006-01-24	Vertex Pharmaceuticals Incorporated	
	3	6664247	B2	2003-12-16	Bebbington et al.	
	4	6653300	B2	2003-11-25	Bebbington et al.	
	5	7087603	B2	2006-08-08	Bebbington et al.	
	6	6656939	B2	2003-12-02	Bebbington et al.	
	7	3755322		1973-08-28	Ciba-Geigy Corporation	
	8	6841579	B1	2005-01-11	Sugen, Inc.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10692355
Filing Date	2003-10-23
First Named Inventor	Robert Davies
Art Unit	1624
Examiner Name	Kahsay Habte
Attorney Docket Number	VPI/00-129-1 DIV US

9	6727251	B2	2004-04-27	Bebbington et al.	
10	6743791	B2	2004-06-01	Vertex Pharmaceuticals Incorporated	
11	7253187	B2	2007-08-07	Vertex Pharmaceuticals Incorporated	
12	6949544	B2	2005-09-27	Vertex Pharmaceuticals Incorporated	
13	6642227	B2	2003-11-04	Vertex Pharmaceuticals Incorporated	
14	7084159	B2	2006-08-01	Vertex Pharmaceuticals Incorporated	
15	6093716		2000-07-25	Celltech Therapeutics, Limited	
16	6277989	B1	2001-08-21	Scios, Inc.	
17	6579983	B1	2003-06-17	Celltech R&D Limited	
18	6884804	B2	2005-04-26	Vertex Pharmaceuticals Incorporated	
19	6184226	B1	2001-02-06	Scios Inc.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10692355
Filing Date	2003-10-23
First Named Inventor	Robert Davies
Art Unit	1624
Examiner Name	Kahsay Habte
Attorney Docket Number	VP/00-129-1 DIV US

20	6589958	B1	2003-07-08	Bristol-Myers Squibb Pharma Company	
21	6825190	B2	2004-11-30	Vertex Pharmaceuticals Incorporated	
22	6686452	B2	2004-02-24	Vertex Pharmaceuticals Incorporated	
23	7098330	B2	2006-08-29	Vertex Pharmaceuticals Incorporated	
24	6660731	B2	2003-12-09	Vertex Pharmaceuticals Incorporated	
25	6613776	B2	2003-09-02	Vertex Pharmaceuticals Incorporated	
26	6638926	B2	2003-10-28	Vertex Pharmaceuticals Incorporated	
27	6610677	B2	2003-08-26	Vertex Pharmaceuticals Incorporated	
28	7115739	B2	2006-10-03	Vertex Pharmaceuticals Incorporated	
29	7179826	B2	2007-02-20	Vertex Pharmaceuticals Incorporated	
30	6846928	B2	2005-01-25	Vertex Pharmaceuticals Incorporated	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10692355
Filing Date	2003-10-23
First Named Inventor	Robert Davies
Art Unit	1624
Examiner Name	Kahsay Habte
Attorney Docket Number	VPI/00-129-1 DIV US

31	7091343	B2	2006-08-15	Vertex Pharmaceuticals Incorporated	
32	4540698		1985-09-10	Mitsui Toatsu Chemicals Incorporated	
33	4711951		1987-12-08	Pharmacia Aktiebolag	
34	5124441		1992-06-23	Pharmacia Aktiebolag	
35	6562971	B2	2003-05-13	BASF Aktiengesellschaft	

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S. PATENT APPLICATION PUBLICATIONS

Remove

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20020065270	A1	2002-05-30	Bristol-Myers Squibb Company	
	2	20010018436	A1	2001-08-30	Tularik Inc.	
	3	20020052386	A1	2002-05-02	Armistead et al.	
	4	20030092714	A1	2003-05-15	Cao et al.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10692355
Filing Date	2003-10-23
First Named Inventor	Robert Davies
Art Unit	1624
Examiner Name	Kahsay Habte
Attorney Docket Number	VPI/00-129-1 DIV US

5	20050038023	A1	2005-02-17	Bebbington et al.	
6	20040229875	A1	2004-11-18	Cao et al.	
7	20030087922	A1	2003-05-08	Bethiel et al.	
8	20040157893	A1	2004-08-12	Bebbington et al.	
9	20030069239	A1	2003-04-10	Cytovia, Inc.	
10	20030069248	A1	2003-04-10	Chakravarty et al.	
11	20030087922	A1	2003-05-08	Bethiel et al.	
12	20030187002	A1	2003-10-02	Mortlock et al.	
13	20060270660	A1	2006-11-30	Charrier et al.	
14	20030096816	A1	2003-05-22	Cao et al.	
15	20040023963	A1	2004-02-05	Cao et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10692355
Filing Date	2003-10-23
First Named Inventor	Robert Davies
Art Unit	1624
Examiner Name	Kahsay Habte
Attorney Docket Number	VP/00-129-1 DIV US

If you wish to add additional U.S. Published Application citation information please click the Add button. [Add](#)

FOREIGN PATENT DOCUMENTS

[Remove](#)

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	0136976	EP	A2	1985-04-10	Ciba-Geigy AG		<input type="checkbox"/>
	2	0012497	WO	A2	2000-03-09	Scios Inc.		<input type="checkbox"/>
	3	0144242	WO	A1	2001-06-21	Bristol-Myers Squibb Co.		<input type="checkbox"/>
	4	0247690	WO	A1	2002-06-20	Cytovia, Inc.		<input checked="" type="checkbox"/>
	5	0224667	WO	A1	2002-03-28	Merck Patent GMBH		<input type="checkbox"/>
	6	9614843	WO	A2	1996-05-23	Cor Therapeutics, Inc.		<input type="checkbox"/>
	7	9509851	WO	A1	1995-04-13	Ciba-Geigy AG		<input type="checkbox"/>
	8	9709325	WO	A1	1997-03-13	Signal Pharmaceuticals, Inc.		<input type="checkbox"/>
	9	9719065	WO	A1	1997-05-29	Cellecth Therapeutics Limited		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10692355
Filing Date	2003-10-23
First Named Inventor	Robert Davies
Art Unit	1624
Examiner Name	Kahsay Habte
Attorney Docket Number	VP1/00-129-1 DIV US

10	9811095	WO	A1	1998-03-19	Celltech Therapeutics Limited		<input type="checkbox"/>
11	9941253	WO	A1	1999-08-19	Tularik Inc.		<input type="checkbox"/>
12	0140215	WO	A1	2001-06-07	Pfizer Products Inc.		<input type="checkbox"/>
13	0147879	WO	A1	2001-07-05	Icos Corporation		<input type="checkbox"/>
14	9918781	WO	A1	1999-04-22	Cytovia, Inc.		<input type="checkbox"/>
15	0021955	WO	A1	2000-04-20	Zeneca Limited		<input type="checkbox"/>
16	0039101	WO	A1	2000-07-06	AstraZeneca UK Limited		<input type="checkbox"/>
17	0164655	WO	A1	2001-09-07	AstraZeneca AB		<input type="checkbox"/>
18	0413140	WO	A1	2004-02-12	Vertex Pharmaceuticals Incorporated		<input type="checkbox"/>
19	0125220	WO	A1	2001-04-12	Kinetix Pharmaceuticals Inc.		<input type="checkbox"/>
20	0279197	WO	A1	2002-10-10	Vertex Pharmaceuticals Incorporated		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10692355
Filing Date	2003-10-23
First Named Inventor	Robert Davies
Art Unit	1624
Examiner Name	Kahsay Habte
Attorney Docket Number	VPI/00-129-1 DIV US

21	0139777	WO	A1	2001-06-07	OSI Pharmaceutical's, Inc.	<input type="checkbox"/>
22	0302312	EP	A2	1989-02-08	Bayer AG	<input type="checkbox"/>
23	0218346	WO	A1	2002-03-07	Pfizer Products Inc.	<input type="checkbox"/>
24	9208715	WO	A1	1992-05-29	Nissan Chemical Industries, Ltd.	<input type="checkbox"/>
25	0112621	WO	A1	2001-02-22	Vertex Pharmaceuticals Incorporated	<input type="checkbox"/>
26	9515758	WO	A1	1995-06-15	Rhonepoulenc Rorer Pharmaceuticals Inc.	<input type="checkbox"/>
27	0078757	WO	A1	2000-12-28	Shionogi Bioresearch Corp.	<input type="checkbox"/>
28	0059509	WO	A1	2000-10-12	Novartis AG	<input type="checkbox"/>
29	9816502	WO	A1	1998-04-23	Warner-Lambert Company	<input type="checkbox"/>
30	9947154	WO	A1	1999-09-23	Cytovia, Inc.	<input type="checkbox"/>
31	9965897	WO	A1	1999-12-23	Chiron Corporation	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10692355
Filing Date	2003-10-23
First Named Inventor	Robert Davies
Art Unit	1624
Examiner Name	Kahsay Habte
Attorney Docket Number	VPI/00-129-1 DIV US

If you wish to add additional Foreign Patent Document citation information please click the Add button [Add](#)

NON-PATENT LITERATURE DOCUMENTS

[Remove](#)

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	Wiener, J.R. et al., "Decreased Src Tyrosine Kinase Activity Inhibits Malignant Human Ovarian Cancer Tumor Growth in a Nude Mouse Model," Clinical Cancer Research, 5, 2164-2170 (1999).	<input type="checkbox"/>
	2	Warner, S.L. et al, "Targeting Aurora-2 Kinase in Cancer," Mol. Cancer Thera., 2, 589-585, 2003.	<input type="checkbox"/>
	3	Wagman, A.S. et al, "Discovery and Development of GSK3 Inhibitors for the Treatment of Type 2 Diabetes," Current Pharmaceutical Design, 10, 1105-1137 (2004).	<input type="checkbox"/>
	4	Nezu, Y. et al., "Dimethoxypyrimidines as Novel Herbicides. Part 2. Synthesis and Herbicidal Activity of Dimethoxyphenoxyphenoxydimidines and Analogues," Pestic. Sci., 47: 115-124 (1996).	<input type="checkbox"/>
	5	Tanaka, T.U. et al., "Evidence that the Ipl1-Sli15 (Aurora Kinase-INCENP) Complex Promotes Chromosome Bi-orientation by Altering Kinetochore-Spindle Pole Connections," Cell, 108, 317-329 (2002).	<input type="checkbox"/>
	6	Staley, C.A. et al., "Decreased Tumorigenicity of a Human Colon Adenocarcinoma Cell Line by an Antisense Expression Vector Specific for c-Src," Cell Growth & Differentiation, 8: 269-274 (1997).	<input type="checkbox"/>
	7	Soriano, P. et al., "Targeted Disruption of the C-SIC PmtOncogene Leads to Osteopetrosis in Mice," Cell, 64, 693-702, (1991).	<input type="checkbox"/>
	8	Campbell, S.F. et al., "2,4-Diamino-6,7-dimethoxyquinazolines. 3,2-(4-Heterocyclylpiperazin-1-yl) Derivatives as α 1-Adrenoceptor Antagonists and Antihypertensive Agents," J. Med. Chem., 30, 1794-1798 (1987).	<input type="checkbox"/>
	9	Casanova, B. et al., "Revisión crítica de la patogenia actual de la esclerosis múltiple y futuras direcciones posibles," Rev. Neurol, 28 (9): 909-915 (1999).	<input checked="" type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10692355
Filing Date	2003-10-23
First Named Inventor	Robert Davies
Art Unit	1624
Examiner Name	Kahsay Habte
Attorney Docket Number	VPI/00-129-1 DIV US

10	Biagi et al., "Synthesis of 4,6 Disubstituted and 4,5,6-Trisubstituted-2-Phenyl-pyrimidines and Their Affinity Towards A1 Adenosine Receptors", <i>Il Farmaco.</i> , 52(1), 61-65 (1997).	<input type="checkbox"/>
11	Simone, J.V., "Oncology: Introduction" in <i>Cecil Textbook in Medicine</i> , 20th ed., Vol. 1, 1004-1010 (1996).	<input type="checkbox"/>
12	Coleman, R.A., "The Biological Evaluation of New Compounds" in <i>Medicinal Chemistry: Principles and Practice</i> , King, Frank D. ed, Royal Society of Chemistry, 53-66 (1994).	<input type="checkbox"/>
13	The CONDENSED CHEMICAL DICTIONARY, Sixth Edition by Arthur and Elizabeth Rose, 38 (1961).	<input type="checkbox"/>
14	Damasio, A.R., "Alzheimer's Disease and Related Dementia," in <i>Cecil Textbook of Medicine</i> , 20th ed., 2: 1992-1996 (1996).	<input type="checkbox"/>
15	Rogers, E. et al., "The aurora kinase AIR-2 functions in the release of chromosome cohesion in <i>Caenorhabditis elegans</i> meiosis," <i>J. Cell Biol.</i> , 157(2): 219-229 (2002).	<input type="checkbox"/>
16	Ali et al., "Palladium-Catalyzed Cross Coupling Reactions of Arylboronic Acids with Pk-Deficient Heteroaryl Chlorides" <i>Tetrahedron Vol. 48, No. 37, pp. 8117-8126</i> (1992).	<input type="checkbox"/>
17	Frame, M.C., "Src in cancer: deregulation and consequences for cell behaviour," <i>Biochimica et Biophysica Acta</i> 1602, 114- 130 (2002).	<input type="checkbox"/>
18	Frampton, J.E. et al., "Pentoxifylline (Oxpentifylline) - A Review of its Therapeutic Efficacy in the Management of Peripheral Vascular and Cerebrovascular Disorder," <i>Drugs & Aging</i> , 7(6): 480-503 (1995)	<input type="checkbox"/>
19	Ganellin, C.R., "Past Approaches to Discovering New Drugs as Medicines" in <i>Medicinal Chemistry, Principles and Practices</i> . King, Frank D. ed, Royal Society of Chemistry, 189-205 (1994).	<input type="checkbox"/>
20	Hamdane, M. et al., "A Therapeutic Target in Alzheimer Neurodegeneration," <i>J. Mol. Neurosci.</i> , 19(3): 275-87 (2002).	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number	10692355
Filing Date	2003-10-23
First Named Inventor	Robert Davies
Art Unit	1624
Examiner Name	Kahsay Habte
Attorney Docket Number	VP/00-129-1 DIV US

21	Hardt, S.E. et al., "Glycogen Synthase Kinase-3 β - A Novel Regulator of Cardiac Hypertrophy and Development," Circulation Research, 90: 1055-1063 (2002).	<input type="checkbox"/>
22	Nezu, Y. et al., "Dimethoxypyrimidines as Novel Herbicides. Part 1. Synthesis and Herbicidal Activity of Dimethoxyphenoxyphenoxydimidines and Analogues," Pestic. Sci., 47: 103-113 (1996).	<input type="checkbox"/>
23	Heaney, F. et al., "Pyrimidine annelated heterocycles—synthesis and cycloaddition of the first pyrimido[1,4]diazepine N-oxides," J. Chem. Soc., Perkin Trans. 1, 622-632 (2001).	<input type="checkbox"/>
24	Lee, S.J. et al., "Discovery of Potent Cyclic GMP Phosphodiesterase Inhibitors. 2-Pyridyl- and 2-Imidazolyquinazolines Possessing Cyclic GMP Phosphodiesterase and Thromboxane Synthesis Inhibitory Activities," J. Med. Chem., 38 (18): 3547-3557 (1995).	<input type="checkbox"/>
25	Okafor, C.O., "Studies in the Heterocyclic Series. X. 1,3,8-Triazaphenothiazine Ring System, a New Phenothiazine Ring," J. Org. Chem., 40(19): 2753-2755 (1975).	<input type="checkbox"/>
26	Jambhekar, S.S., "Biopharmaceutical Properties of Drug Substances" in Principles of Medicinal Chemistry, 4th ed., 12-24, (1995).	<input type="checkbox"/>
27	Layzer, R.B., "Section Five - Degenerative Diseases of the Nervous System" in Cecil Textbook of Medicine, 20th ed., 2: 2050-2057 (1996).	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.